Exalpha Biologicals, Inc.

Accelerating the Pace of Discovery

Product Highlight

Mouse anti-M13 phage coat protein g8p

Antibodies recognising M13 filamentous phage coat proteins are instrumental in the selection and detection of phages expressing specific antibody fragments or peptide sequences at their surface. The monoclonal antibodies manufactured and supplied by Exalpha react with either the pIII (g3p) or pVIII (g8p) proteins of M13 filamentous bacteriophage. All antibodies are available in a purified format. The antibodies are fully validated and are suitable for a wide range of techniques including:

  • Flow Cytometry
  • Western Blot
  • Immunohistochemistry
  • Immunoprecipitation
For more information, click here for our M13 Bacteriophage information page.


Two more of our excellent products have been published by PubMed:

Potential actionable targets in appendiceal cancer detected by immunohistochemistry, fluorescent in situ hybridization, and mutational analysis
Borazanci, E., et al., J. Gastrointest. Oncol., 8, 164-172 (2017)
Using Exalpha SPARC Antibody (Cat. No. X1867P)

Molecular mechanism underlying the pharmacological interactions of the protein kinase C-β inhibitor enzastaurin and erlotinib in non-small cell lung cancer cells
Steen, N.V., et al., Am. J. Cancer Res., 7, 816-830 (2017)
Using Exalpha's FITC labeled anti PY20 Antibody (Cat. No. X1017)

Exalpha Biologicals, Inc.

Cytokeratin 17

  • Product Code: X1736M
  • Size: 100 µg
  • Price (USD): $335

Cat #

X1736M		 Quantity:      

Data Sheet

Product Name

Cytokeratin 17







Product Type

Monoclonal Antibody


Human, Rat


Western Blot, Immunohistochemistry, Immunocytochemistry, Flow Cytometry


Protein A/G Chromatography


100 µg

Price (USD)



Cytokeratins are a subfamily of intermediate filament proteins and are characterized by a remarkable biochemical diversity, represented in human epithelial tissues by at least 20 different polypeptides. They range in molecular weight between 40 kDa and 68 kDa and isoelectric pH between 4.9 – 7.8. The individual human cytokeratins are numbered 1 to 20. The various epithelia in the human body usually express cytokeratins which are not only characteristic of the type of epithelium, but also related to the degree of maturation or differentiation within an epithelium. Cytokeratin subtype expression patterns are used to an increasing extent in the distinction of different types of epithelial malignancies. The cytokeratin antibodies are not only of assistance in the differential diagnosis of tumors using immunohistochemistry on tissue sections, but are also a useful tool in cytopathology and flow cytometric assays.


Hybridoma produced by the fusion of splenocytes from BALB/c mice immunized with cytoskeletal preparation from rat colon and mouse X63 Ag 8.653 myeloma cells.

Positive Control

This antibody reacts with cytokeratin 17 in basal layers of pseudo-stratified and transitional epithelia.


Provided as solution in phosphate buffered saline with 0.08% sodium azide

Customer Storage

Product should be stored at -20°C. Aliquot to avoid freeze/thaw cycles

Database Links:



1. Guelstein, V. I., et al. (1988). Monoclonal antibody mapping of keratins 8 and 17 and of vimentin in normal human mammary gland, benign tumors, dysplasias and breast cancer,
Int J Cancer 42, 147-53.
2. Troyanovsky, S. M., et al. (1989). Patterns of expression of keratin 17 in human epithelia: dependency on cell position, J Cell Sci 93, 419-26.
3. Smedts, F., et al. (1990). Keratin expression in cervical cancer, Am J Pathol 141, 497-511.
4. Wetzels, R. H., et al. (1991). Basal cell-specific and hyperproliferation-related keratins in human breast cancer. Am J Pathol 138, 751-763.
5. Wetzels, R. H., et al. (1992). Laminin and type VII collagen distribution in different types of human lung carcinoma: correlation with expression of keratins 14, 16, 17 and 18. Histopathology 20, 295-303.
6. Smedts, F., et al. (1992). Basal-cell keratins in cervical reserve cells and a comparison to
their expression in cervical intraepithelial neoplasia. Am J Pathol 140, 601-612.
7. Smedts, F., et al. (1994). Detection of keratin subtypes in routinely processed cervical tissue: implications for tumour classification and the study of cervix cancer aetiology. Virchows Arch 425, 145-155.
8. Litvinov, S. V., et al. (1996). Expression of Ep-CAM in cervical squamous epithelia correlates with an increased proliferation and the disappearance of markers for terminal differentiation. Am J Pathol 148, 865-875.
9. Moll, I., Moll, R. (1991). Comparative cytokeratin analysis of sweat gland ducts and eccrine poromas. Arch Dermatol Res. 283, 300- 09.
10. De Jong, E., van Vlijmen, I., van Erp, P., Ramaekers, F., Troyanowsky, S., Van de Kerkhof, P. (1991). Monoclonal anti-keratin 17: A useful marker for anti-psoriatic therapies. Arch Dermatol Res 283, 480-82.
11. Demirkesen, C., Hoede, N., Moll, R. (1995). Epithelial markers and differentiation in adnexal neoplasms of the skin: an immunohistochemical study including individual cytokeratins. J Cutan Pathol 22, 518-35.
12. Moll, R., et al. (1995). Differenzierungsmarker bei gynäkologischen Tumoren: Methodische und diagnostische Aspekte. In: Aktuelle Aspekte der Tumorimmunologie in der Gynäkologie. W Zuckschwerdt Verlag.